Please upgrade your browser.
A mother from Kent dying of a rare form of cancer has hit out at the NHS after she was refused the only drug that could help prolong her life.
The trial that Cutright enrolled in through the institute - part of Southern Illinois University School of Medicine - pays for the medicine Cutright hopes will halt or slow the progression of her adrenal cancer, which has spread to both lungs.
Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma.
Physicians at Henry Ford Hospital have found that infection with the hepatitis C virus increases the risk for developing kidney cancer.
"Cipla will launch ''sorafenib tosylate'' under the brand Soranib, the generic version of Nexavar at less than 1/10th of Bayer''s price of Rs 2.8 lakh for a month''s treatment," Cipla Joint Managing Director Amar Lulla told PTI over telephone.
The rationing body NICE has since refused to approve ten such drugs. Experts say the rulings cut short up to 20,000 lives.
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC).
The researchers found that survivors of childhood cancers face health risks that shorten their life span by about 10 years on average. The loss in life expectancy varied for different types of cancer. Survivors of kidney cancer died about 4 years earlier . . .
Life-saving cancer drugs are still not available on the NHS nearly 18 months after the Government promised to improve access to vital medicines, the Conservatives claim.
In addition to our ongoing Phase 3 clinical trial of once-daily, oral tivozanib in patients with advanced RCC, we are currently conducting multiple clinical trials of tivozanib . . .
|Powered by NeonCRM|